Showing results (251-260 of 407) with videos related to

Sort By:
Pageof 41
Clinical and Experimental Rheumatology|April 22, 2015
The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritisMartin Feuchtenberger, Stefan Kleinert, Eva-Christina Scharbatke, et al.
Scientific Reports|December 20, 2023
Machine learning identifies right index finger tenderness as key signal of DAS28-CRP based psoriatic arthritis activitySamuel Rischke, Sorwe Mojtahed Poor, Robert Gurke, et al.
Lancet (London, England)|July 27, 2020
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trialGerd R Burmester, Frank Buttgereit, Corrado Bernasconi, et al.
The Journal of Rheumatology|March 19, 2013
Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndromeLorena Martinez-Gamboa, Karsten Lesemann, Ulrike Kuckelkorn, et al.
Annals of the Rheumatic Diseases|July 9, 2026
A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trialPaul Emery, Michael E Weinblatt, Vivian P Bykerk, et al.
Lancet (London, England)|February 16, 2024
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trialJuergen Rech, Koray Tascilar, Melanie Hagen, et al.
Clinical and Experimental Rheumatology|March 12, 2016
Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Rheumatology and Therapy|October 9, 2022
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 StudyBernard G Combe, Yoshiya Tanaka, Maya H Buch, et al.
RMD Open|February 8, 2023
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitisGerd R Burmester, Stanley B Cohen, Kevin L Winthrop, et al.
Rheumatology (Oxford, England)|April 25, 2023
Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED studyGurjit S Kaeley, Georg Schett, Philip G Conaghan, et al.
Pageof 41